We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Simcyp Limited Acquired by Certara

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Simcyp will operate as a business unit within Certara maintaining its Consortium business model and its focus on population-based PBPK/PD modelling and simulation services and software which it provides to the industrial pharmaceutical community.

The acquisition will significantly strengthen Simcyp’s ability to relate molecular structure to drug disposition through collaborative links with Tripos and extend Simcyp’s reach into clinical trial simulation, IVIVC and PK/PD modelling and simulation through collaborative links with Pharsight.

As a Certara company, Simcyp becomes an integral part of the Certara vision to provide a ‘joined-up’ drug-development information/modelling and simulation platform that will help drive-up efficiencies in R&D and drive-down operating costs within their global pharmaceutical industry clients.

In making the announcement, John Evans, Managing Director at Simcyp said: “We’re very pleased to become part of the Certara team. The acquisition by Certara will allow Simcyp to focus on its core competence whilst allowing us to draw on the broader drug development expertise available within the Certara family. Clients from across the spectrum of drug discovery and development will have access to a broader range of products and services, which will be enhanced by combining the attributes of Tripos, Simcyp, and Pharsight science and functionality.”

Certara’s President and Chief Executive Officer, Jim Hopkins, said: “We’re excited to add Simcyp to the Certara family, as a complement to Pharsight and Tripos. With the capabilities offered by Simcyp’s proprietary technology, combined with our existing software products and scientific consulting services, we expect to provide significant synergies to our mutual clients. From a translational science perspective, Simcyp’s preclinical simulation technologies, which include prediction of drug/drug interactions, fit perfectly between Certara’s existing discovery and clinical research offerings, thus enabling an end-to-end solution.”

The shareholders of Simcyp were advised by Livingstone Partners, the international mid-market corporate finance advisory firm with offices in London and Chicago, and by DLA Piper one of the UK’s leading law firms.